Compare Dr. Reddys with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs JUBILANT LIFE SCIENCES - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB JUBILANT LIFE SCIENCES DR. REDDYS LAB/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 36.6 10.1 362.3% View Chart
P/BV x 4.3 1.1 379.1% View Chart
Dividend Yield % 0.6 1.3 41.8%  

Financials

 DR. REDDYS LAB   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
JUBILANT LIFE SCIENCES
Mar-19
DR. REDDYS LAB/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs2,875898 320.2%   
Low Rs1,888618 305.7%   
Sales per share (Unadj.) Rs930.2572.0 162.6%  
Earnings per share (Unadj.) Rs117.436.2 324.1%  
Cash flow per share (Unadj.) Rs185.859.5 312.1%  
Dividends per share (Unadj.) Rs20.004.50 444.4%  
Dividend yield (eoy) %0.80.6 141.4%  
Book value per share (Unadj.) Rs844.4301.9 279.7%  
Shares outstanding (eoy) m166.07159.28 104.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.61.3 193.3%   
Avg P/E ratio x20.320.9 97.0%  
P/CF ratio (eoy) x12.812.7 100.7%  
Price / Book Value ratio x2.82.5 112.4%  
Dividend payout %17.012.4 137.1%   
Avg Mkt Cap Rs m395,496120,694 327.7%   
No. of employees `00022.02.4 919.1%   
Total wages/salary Rs m33,56219,260 174.3%   
Avg. sales/employee Rs Th7,032.838,120.6 18.4%   
Avg. wages/employee Rs Th1,527.98,058.4 19.0%   
Avg. net profit/employee Rs Th887.72,414.3 36.8%   
INCOME DATA
Net Sales Rs m154,48291,108 169.6%  
Other income Rs m3,375357 944.3%   
Total revenues Rs m157,85791,466 172.6%   
Gross profit Rs m31,78217,390 182.8%  
Depreciation Rs m11,3483,709 306.0%   
Interest Rs m8892,198 40.4%   
Profit before tax Rs m22,92011,840 193.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m3,8583,268 118.1%   
Profit after tax Rs m19,5005,770 337.9%  
Gross profit margin %20.619.1 107.8%  
Effective tax rate %16.827.6 61.0%   
Net profit margin %12.66.3 199.3%  
BALANCE SHEET DATA
Current assets Rs m111,10145,848 242.3%   
Current liabilities Rs m58,97320,897 282.2%   
Net working cap to sales %33.727.4 123.2%  
Current ratio x1.92.2 85.9%  
Inventory Days Days7957 139.7%  
Debtors Days Days9451 184.9%  
Net fixed assets Rs m101,24565,498 154.6%   
Share capital Rs m830159 521.0%   
"Free" reserves Rs m139,40647,930 290.9%   
Net worth Rs m140,23648,089 291.6%   
Long term debt Rs m22,00042,429 51.9%   
Total assets Rs m224,656114,685 195.9%  
Interest coverage x26.86.4 419.3%   
Debt to equity ratio x0.20.9 17.8%  
Sales to assets ratio x0.70.8 86.6%   
Return on assets %9.16.9 130.6%  
Return on equity %13.912.0 115.9%  
Return on capital %14.912.4 120.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,67312,422 713.8%   
Fx outflow Rs m19,10417,227 110.9%   
Net fx Rs m69,569-4,805 -1,447.8%   
CASH FLOW
From Operations Rs m28,70411,215 255.9%  
From Investments Rs m-7,727-10,118 76.4%  
From Financial Activity Rs m-21,3266,574 -324.4%  
Net Cashflow Rs m-3147,612 -4.1%  

Share Holding

Indian Promoters % 25.5 45.6 55.9%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 5.4 8.7 62.1%  
FIIs % 35.3 21.2 166.5%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 21.1 72.5%  
Shareholders   75,885 23,815 318.6%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Surges 1,266 Points; Nifty Ends Above 9,100 Mark(Closing)

Indian share markets witnessed buying interest throughout the day and ended on a strong note.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

A Safe Stock to Lockdown Now(The 5 Minute Wrapup)

Apr 2, 2020

The market crashc has made strong, established brands attractive. Here's a stock to make the most of this opportunity...

The Insiders See a Buying Opportunity in These Smallcaps Amid Coronavirus Outbreak(Profit Hunter)

Mar 31, 2020

The promoters are buying these smallcaps amid the coronavirus outbreak.

How to Identify a Market Rebound(Fast Profits Daily)

Mar 27, 2020

This very useful indicator can spot a market bottom.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Apr 9, 2020 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - PIRAMAL ENTERPRISES COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS